ClinicalTrials.gg
RecruitingNCT02071134Updated Nov 12, 2026

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

An observational study in Parkinson's Disease, sponsored by Boston Scientific Corporation. Recruiting at 87 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Boston Scientific Corporation · Observational

How we know

From the registry’s dates

  • Started Mar 2014; still recruiting 12 years 8 months later.
Updated Nov 12, 20262 sites added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Parkinson Disease by Boston Scientific Corporation — 3 open to participants now, 3 under way, none of them phase 3. Parkinson Disease · Boston Scientific Corporation.

Started
2014
the only one that year
Observational
3 of 10
3 open now
Registered
4th of 10
by date

Among the 10 studies in Parkinson Disease by Boston Scientific Corporation, this one is the only one that started in 2014, is one of 3 observational ones, and was the 4th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 10 studies in Parkinson Disease by Boston Scientific Corporation are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Parkinson Disease by Boston Scientific Corporation, or all of them as a file.
02

Study summary

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease.

The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated.

Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.

Read the detailed description

The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS system in the treatment of Parkinson's disease.

Subjects' improvement in disease symptoms and overall Quality of life will be assessed during the study following DBS and compared with baseline. Additionally, the utilization of Image Guided Programming (IGP) when used as a planning tool for programming of patients is also evaluated.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Deep brain stimulation
  • Parkinson's disease
  • Vercise
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with symptoms of Parkinson's disease that are not adequately controlled with medication

Eligibility criteria

Key Inclusion Criteria:

  • Meets criteria established in locally applicable Vercise System Direction for Use
  • At least 18 years old

Key Exclusion Criteria:

  • Meets any in the Vercise System locally applicable Directions for Use

Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Target follow-up
3 Years
Patient registry
Yes

Groups and cohorts

  • Parkinson's disease

    Subjects with Parkinson's disease who will receive Vercise DBS for deep brain stimulation.

    Device: Deep Brain Stimulation (DBS)

Interventions

  • DeviceDeep Brain Stimulation (DBS)

    Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.

    Also known as: Vercise DBS System, Boston Scientific

06

What researchers measure

Primary outcomes

  1. Improvement in patient's quality of life (QoL) during the study as compared with baseline

    Change in quality of life assessments during the study as compared with baseline

    Time frame: up to 3 years

Other outcomes

  1. Change in parkinson's disease symptoms as determined by UPDRS scores during the study as compared with baseline

    Change in patient's motor symptoms as determined by UPDRS during the study as compared with baseline

    Time frame: up to 3 years

  2. Change in medication usage during the study as compared with baseline

    Time frame: up to 3 years

  3. Impression of change scores during the study as compared with baseline

    Impression of change scores during the study as compared with baseline

    Time frame: 3 years

07

Study locations

35 of 87 sites recruiting
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2014 (actual). Primary completion is estimated for Dec 2038, 297 months after the start.

Of 60 industry-sponsored observational studies under Parkinson Disease, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 297 months is above that.

Counting every sponsor, half of 441 studies reached it within 47 months; a quarter within 22 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2014
First posted
Feb 25, 2014
StartActual
Mar 4, 2014
Primary completionEst.
Dec 2038
CompletionEst.
Dec 2038
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (1 Germany, 1 Israel)
  • Universitaetsklinikum Tuebingen · Tübingen, Germany
  • Sheba Medical Center · Tel HaShomer, Israel
Show 1 removed
  • Sheba Medical Center · Tel Litwinsky, Israel
across 2 updates, Oct 13, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    1 site added, 1 site removed
    Show site
    • Sheba Medical Center · Tel HaShomer, Israel
    Show 1 removed
    • Sheba Medical Center · Tel Litwinsky, Israel
    + 1 other change: verification date
  2. Oct 13, 2026
    1 site added
    Show site
    • Universitaetsklinikum Tuebingen · Tübingen, Germany
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02071134
Responsible party
Sponsor
First posted
Feb 25, 2014
Start date
Mar 4, 2014
Primary completion
Dec 2038 (estimated)
Completion
Dec 2038 (estimated)
Last update
Nov 12, 2026

Study contacts

Heleen Scholtes
Contact
BSNClinicalTrials@bsci.com
855-213-9890
Alison Lewis
Contact
BSNClinicalTrials@bsci.com
855-213-9890
Natalie Bloom Lyons
study director · Boston Scientific Neuromodulation Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion